Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma
Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and CTLA-4, which has the potential to boost immune surveillance in tumors. The goal of this clinical trial is to evaluated the efficacy and safety of cadonilimab combined with TACE in patients with intermediate-stage unresectable hepatocellular carcinoma.
Hepatocellular Carcinoma
DRUG: Cadonilimab+TACE
Objective response rate (ORR), ORR is defined as the percentage of participants who have a confirmed complete response or partial response according to RECIST 1.1., Up to 1 year
Progression free survival (PFS), PFS is defined as the time from enrollment of the trial to the first documented disease progression or death due to any cause., Up to two years|Overall survival (OS), The duration from the date of recruitment to the date of death from any cause., Up to two years|Adverse events (safety), Adverse events (safety ) will be evaluated according to the NCI CTCAE Version 5.0.The number and severity of treatment-related side effects, including AE and SAE, will be recorded during treatment., Up to two years
Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and CTLA-4, which has the potential to boost immune surveillance in tumors. The goal of this clinical trial is to evaluated the efficacy and safety of cadonilimab combined with TACE in patients with intermediate-stage unresectable hepatocellular carcinoma.